Mobile stroke units can avert costs in delivery of acute stroke care once optimal thresholds are reached, a cost-consequence analysis finds. Avoidance of secondary interhospital transfers account for substantial potential savings.
An expert attendee draws from a wealth of presentations to share why a handful of new (and old) studies are likely to change practice in stroke care.
Mobile stroke units have been shown to accelerate patient evaluation and treatment. Now, for the first time, this speedier management has been shown to translate to clinical benefit for patients.
Mobile stroke units are gaining significant traction in the U.S. and around the world. A new paper looks back on the units’ time-to-treatment effects — and ahead to outcome and cost impacts.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A study on Cleveland Clinic’s mobile stroke unit reveals one characteristic that seems to particularly drive early IV thrombolysis delivery.
Practice may not make perfect in healthcare, but it can sure make for greater efficiency and effectiveness. This study of our mobile stroke unit’s evolution over three years is a case in point.
A Cleveland Clinic study presented at the 2018 International Stroke Conference suggests these units may help bypass interhospital transfers for patients requiring thrombectomy.
The newly published DEFUSE 3 trial joins the DAWN trial in support of extending the time window for endovascular thrombectomy in selected patients with acute ischemic stroke.
Something’s going right in acute stroke therapy: Medicare data show that one-year mortality fell 18 percent from 2009 to 2013 in tandem with a 60 percent rise in IV tPA use.
A slew of randomized trials have confirmed the superiority of endovascular therapy over IV t-PA alone for acute ischemic stroke. Here’s how endovascular therapies can be best deployed to yield the greatest patient benefits.